Free Newsletter
Bioengineered plant makes antibodies against HIV
A group of Swedish researchers say that they have developed a new HIV vaccine that can be produced in plants and has proven effective in mice.
"A major problem with the HIV virus is that it mutates rapidly and therefore exists in several different variants. In other words, it's not possible to create an effective vaccine that is based on the entire virus. Moreover, this would be far too risky. Instead, we have selected a protein, p24, that exists in all HIV viruses and looks roughly the same in the various virus lines," says Ingrid Lindh, author of the dissertation.
It's impossible to transfer a gene directly into a plant. But the researchers got around that obstacle by putting the gene into bacterium and then into a plant. Mice which consumed the plant material produced antibodies that protected them from HIV.
Their next step will involve adding new proteins and molecules into the mix to boost the efficacy of the plant-based vaccine and increase the probability of its success in humans. They also are seeking an ideal plant that could fit easily into a variety of diets and grow around the world. The carrot may be ideal.
- check out the press release
Related Articles:
BIO: Elton John speaks out on AIDS issues
World AIDS day marked by new vaccine progress
Woman's immune system may be key to HIV vax
IAVI maps out a new route to AIDS vaccine
Fauci says HIV vaccine requires a new approach
Comments
Im very optimistic it will be found a cure for HIV. I am suffering the condition since 2 years ago. It is very frustrating live with the condition but i hope they find a vaccine soon so I wont die.
I hope scientists find a vaccine soon for this condition. I am suffering from HIV for a few years now. I am stable since I am taking my medications in a regular basis as prescribed.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession




